Journals / Turkish Journal of Rheumatology(.)Archives of Rheumatology / 2011 / Cilt: 26 - Sayı: 3

Romatoid Artritte Anti-Siklik Sitrulinli Peptid Antikorlar ve Bunların Ekstra-Artiküler Bulgular ile İlişkisi

Anti-Cyclic Citrullinated Peptide Antibodies in Rheumatoid Arthritis and Their Relationship with Extra-Articular Manifestations

Pages
193–198
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

We think that further studies with a larger sample size are necessary to evaluate the relationship between EAM and anti-CCP antibodies

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objectives: In this study, we investigated the relationship between extra-articular manifestations (EAM) and anti-cyclic citrullinated peptide (anti-CCP) antibodies.
📊
Key Findings & Data:Patients and methods: Sixty-seven patients (53 females, 14 males; mean age 57.4±13.5 years; range 26 to 82 years) diagnosed with rheumatoid arthritis (RA) according to the ACR (American College of Rheumatology) criteria between January 2009 - December 2009 were included in the study.
💡
Conclusion & Impact:We think that further studies with a larger sample size are necessary to evaluate the relationship between EAM and anti-CCP antibodies
🔬Design:Research Article
📍Scope:2009 Verileri
⚙️Variables:Domain Parameters

Abstract

Objectives: In this study, we investigated the relationship between extra-articular manifestations (EAM) and anti-cyclic citrullinated peptide (anti-CCP) antibodies. Patients and methods: Sixty-seven patients (53 females, 14 males; mean age 57.4±13.5 years; range 26 to 82 years) diagnosed with rheumatoid arthritis (RA) according to the ACR (American College of Rheumatology) criteria between January 2009 - December 2009 were included in the study. The age, gender, disease duration, and EAMs (rheumatoid nodules, pulmonary nodules, pulmonary fibrosis, keratoconjunctivitis sicca) of each patient were recorded, and the anti-CCP antibody and rheumatoid factor (RF) positivity and serum RF levels were evaluated. Results: Extra-articular manifestations were present in 28 (41.8%) of the patients. Anti-CCP antibodies were present in 34 (50.7%) patients. Positivity of anti-CCP antibodies was found in 16 (57.1%) patients with EAM compared to 18 (46.2%) patients without EAM (p>0.05). Rheumatoid factor positivity was found in 23 (82.1%) patients with EAM compared with 30 (76.9%) patients without EAM (p>0.05). The serum levels of RF were 176.5±201.7 IU/ml in the patients with EAM, and 114.1±144.8 IU/ml in the patients without EAM (p>0.05). The mean serum titers of RF were significantly higher in the patients with pulmonary fibrosis than in those without pulmonary fibrosis (237.8±204.8 IU/ml and 118.9±158.6 IU/ml respectively; p=0.036). Conclusion: It is known that EAMs increase morbidity and mortality in patients with rheumatoid arthritis. Thus, the markers that help identify patients with severe disease have an important role in making a decision for early aggressive treatment. Studies that investigate the relationship between anti-CCP antibodies and EAM have conflicting results. In this study, no relationship was found between the antibodies against citrullinated peptides and the presence of EAMs. We think that further studies with a larger sample size are necessary to evaluate the relationship between EAM and anti-CCP antibodies

Özet

Amaç: Bu çalışmada anti-siklik sitrulinli peptid (anti-CCP) antikorlar ile ekstra-artiküler tutulum (EAT) arasındaki ilişki araştırıldı.Hastalar ve yöntemler: Çalışmaya Ocak 2009 - Aralık 2009 tarihleri arasında ACR (American College of Rheumatology) tanı kriterlerine göre romatoid artrit (RA) tanısı konulan 67 hasta (53 kadın, 14 erkek; ort. yaş 57.4±13.5 yıl; dağılım 26-82 yıl) dahil edildi. Tüm hastaların yaşları, cinsiyetleri, hastalık süreleri ve EAT'leri (romatoid nodül, pulmoner nodül, pulmoner fibroz, keratokonjonktivitis sikka) kaydedildi ve romatoid faktör (RF) ve anti-CCP antikor pozitifliği ve serum RF seviyeleri değerlendirildi.Bulgular: Hastaların 28'inde (%41.8) EAT saptandı. Otuz dört hastada (%50.7) anti CCP antikorlar mevcuttu. AntiCCP antikor pozitifliği EAT'li 16 hastada (%57.1) saptanırken, EAT'si bulunmayan 18 hastada (%46.2) saptandı (p>0.05). Romatoid faktör pozitifliği EAT'li 23 (%82.1) hastada mevcut iken, EAT'si olmayan 30 hastada (%76.9) mevcuttu (p>0.05). Serum RF seviyeleri EAT'li hastalarda 176.5±201.7 IU/ml iken, EAT'siz hastalarda 114.1±144.8 IU/ml idi (p>0.05). Pulmoner fibrozisi olan hastaların ortalama serum RF titreleri pulmoner fibrozisi olmayanlara göre anlamlı şekilde daha yüksek (sırasıyla 237.8±204.8 IU/ml ve 118.9±158.6 IU/ml; p=0.036) idi.Sonuç: Romatoid artritli hastalarda EAT'lerin mortaliteyi ve morbiditeyi artırdığı bilinmektedir. Bu nedenle şiddetli hastalığı olan hastaların saptanmasına yardımcı olan belirleyiciler erken agresif tedaviye karar verilmesinde önemli rol oynamaktadır. Anti-CCP antikorları ile EAT arasındaki ilişkiyi araştıran çalışmalarda çelişkili sonuçlar bulunmuştur. Bu çalışmada CCP pozitifliği ile EAT varlığı arasında herhangi bir ilişki saptanmadı. Anti-CCP antikorları ile EAT arasındaki ilişkiyi değerlendirmek için daha fazla sayıda hasta içeren çalışmalara gereksinim olduğu düşüncesindeyiz

🔖

Cite This Article

ORTANCIL, Ö., ÇOBAN, Ş. Ö., KIRAN, S., ARASLI, M. (2011). Romatoid Artritte Anti-Siklik Sitrulinli Peptid Antikorlar ve Bunların Ekstra-Artiküler Bulgular ile İlişkisi. Turkish Journal of Rheumatology(.)Archives of Rheumatology, Cilt: 26 - Sayı: 3, 193–198. https://ajindex.com/articles/376090

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (8)

  1. De Rycke L, Peene I, Hoffman IE, Kruithof E, Union A, Meheus L, et al. Rheumatoid factor and anticitrullinated protein antibodies in rheumatoid arthritis: diagnostic value, associations with radiological progression rate, and extra-articular manifestations. Ann Rheum Dis 2004;63:1587-93.
  2. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24. van Jaarsveld CH, ter Borg EJ, Jacobs JW, Schellekens GA, Gmelig-Meyling FH, van Booma-Frankfort C, et al. The prognostic value of the antiperinuclear factor, anti- citrullinated peptide antibodies and rheumatoid factor in early rheumatoid arthritis. Clin Exp Rheumatol 1999;17:689-97.
  3. Schellekens GA, Visser H, de Jong BA, van den Hoogen FH, Hazes JM, Breedveld FC, et al. The diagnostic properties of rheumatoid arthritis antibodies recognizing a cyclic citrullinated peptide. Arthritis Rheum 2000;43:155-63. Kroot EJ, de Jong BA, van Leeuwen MA, Swinkels H, van den Hoogen FH, van't Hof M, et al. The prognostic value of anti-cyclic citrullinated peptide antibody in patients with recent-onset rheumatoid arthritis. Arthritis Rheum 2000;43:1831-5. van Zeben D, Hazes JM, Zwinderman AH, Cats A, van der Voort EA, Breedveld FC. Clinical significance of rheumatoid factors in early rheumatoid arthritis: results of a follow up study. Ann Rheum Dis 1992;51:1029-35. Jónsson T, Valdimarsson H. Clinical significance of rheumatoid factor isotypes in seropositive arthritis. Rheumatol Int 1992;12:111-3.
  4. Houssien DA, Jonsson T, Davies E, Scott DL. Clinical significance of IgA rheumatoid factor subclasses in rheumatoid arthritis. J Rheumatol 1997;24:2119-22.
  5. Houssien DA, Jónsson T, Davies E, Scott DL. Rheumatoid factor isotypes, disease activity and the outcome of rheumatoid arthritis: comparative effects of different antigens. Scand J Rheumatol 1998;27:46-53.
  6. Bas S, Genevay S, Meyer O, Gabay C. Anti-cyclic citrullinated peptide antibodies, IgM and IgA rheumatoid factors in the diagnosis and prognosis of rheumatoid arthritis. Rheumatology (Oxford) 2003;42:677-80.
  7. Dündar U, Evcik D, Çakır T, Aktepe O, Altındış M, Kavuncu V. Romatod artritli hastalarda anti-CCP antikorlarının hastalık aktivitesi ve radyolojik hasar ile ilişkisi. Turk J Rheumatol 2005;20:9-14.
  8. Turesson C, Jacobsson LT, Sturfelt G, Matteson EL, Mathsson L, Rönnelid J. Rheumatoid factor and a